Note: Descriptions are shown in the official language in which they were submitted.
T 4502
NOVEL ALKENYLPHENOL DERIVATIVES
This invention relates to a novel class of spirodilactam
derivatives. More particularly, the invention relates to
1,6-diaza[4,4]spirodilactams having a hydro~yaryl- or
cyanatoaryl-containing substituent on each spiro ring nitrogen
atom, wherein the said aryl group contains an unsaturated
hydrocarbyl group substituent.
Unsaturated derivatives of polyhydric phenols are a well known
class of compounds that can be cured or crosslinked to produce
insoluble products that typically exhibit good solvent resistance
and mechanical properties as well as relatively high heat
distortion temperatures. Such unsaturated derivatives are
crosslinked by reaction with catalytic or polyfunctional
stoichiometric curing agents to produce tough, heat resistant
products which are processed by conventional methods into films or
laminates with fibre glass or other reinforcements or into shaped
objects and the crosslinked products are additionally useful in
adhesive formulations.
When the unsaturated phenolic derivative is an ether of a
polyhydric phenol, or is produced from a polyhydric phenol, much of
the technology is broadly conventional. The phenolic ether is
suitably cured or crosslinked as such but additionally the ether is
rearranged to produce a phenol having an unsaturated ortho
substituent (occasionally para) which phenol is also curable. The
disclosure of Zahir, U.S. 4,100,140, is illustrative. The compound
2,2-di(4-hydroxyphenyl~propane, also known as bisphenol A or BPA,
is converted to its sodium salt and reacted with allyl chloride to
produce the diallyl ether of BPA, i.e., 2,2-di(4-allyloxyphenyl)-
propane. This diallyl ether is curable, for example, by heating the
diallyl ether with an imide-containing curing agent. Alternatively,
the diallyl ether is subjected to rearrangement according to the
classical Claisen Rearrangement to produce the corresponding
' , ' ,
ortho-allylphenol, i.e., 2,2-di(4-hydroxy-3-allylphenyl)propane.
The ortho allyl derivative is also curable as by heating with a
bis(maleimide). It is also known to produce an allyl ether of the
ortho-allylphenol and subsequently conduct a second rearrangement
to produce an o,o-diallylphenol derivative. To obtain even grea~er
functionality, an allyl ether of the diallylphenol is produced, all
by conventional technology.
On some occasions, the cured products which provide the more
desirable properties, particularly in high temperature
applications, are those wherein the phenolic derivatives are of
polycyclic structure. It would be of advantage to provide a novel
class of unsaturated derivatives of phenols having a plurali~y of
rings within the molecular structure. Such polycyclic unsaturated
derivatives react with conventional curing agents to produce cured
products having good properties.
The novel spirodilactam derivatives of the invention is a
spirodilactam having the formula
O ~ Z (I)
y- (cH2)m--(R)n (X R )r X
lZ N - (R ' - X) r (R)n- (CH2)m - Y
Z O
wherein R is phenylene, hydroxyphenylene, or cyanatophenylene, R'
is R or aliphatic oE up to 10 carbon atoms, inclusive, X is a
direct valence bond, alkylene of up to ~ carbon atoms, oxo, thio,
sulfonyl, carbonyl, dioxyphenylene, 2,2-di(oxyphenyl)propane,
di(oxyphenyl)sulfone or dioxydiphenylene, each of r, n and m
independently is O or 1, Z independently is ~C(Z')2 in which Z
independently is hydrogen, lower alkyl, lower halo or phenyl, or Z
i5 such that two adjacent carbon atoms form part of a benzene ring,
Y independently is selected from - CH=CH2, or - C=CH.
Preferred are those novel spirodilactams in which the
unsaturated group is in ortho-position relative to the hydroxy- or
cyanato group.
In the embodiment of the above formula wherein the Z moieties
are not part of a fused ring substituent and are therefore acyclic,
:
3 ~
- 3 -
i.e., ~ is \ C(Z')2, illustrative ortho-alkenyl hydroxyaryl-
substituted spirodilactam products include 1,6-di(4-hydroxy-3-
allylphenyl)-1,6-diazaspiro[4,4]nonane-2,7-dione, 1,6-di(3-hydroxy-
4-allyl-5-chlorophenyl)-3,8-dimethyl-1,6-diazaspiro[4,4]nonane-2,7-
dione, 1,6-di[4-(4-hydroxy-3-allylbenzoyl)phenyl]-3-phenyl-1,6-
diazaspiro[4,4]nonane-2,7-dione, 1,6-di(4-hydroxy-3,5-diallyl-
phenyl)-3,3,4,4,8,8,9,9-octamethyl-1,6-diazaspiro[4,4]nonane-2,7-
dione, 1,6-di(4-hydroxy-3-methallylphenyl)-1,6-diazaspiro[4,4]-
nonane-2,7-dione, 1,6-di[4-(4'-hydroxy-3'-crotylbiphenyl)]-3,3-
dimethyl-1,6-diazaspiro[4,4]-nonane-2,7-dione, 1,6-di[2-(4-hydroxy-
3-methallylphenyl)propyl]-1,6-diazaspiro[4,4]nonane-2,7-dione,
1,6-di[4-(4-hydroxy- or 4-cyanato-3-allylphenylisopropyl)phenyl]-
1,6-diazaspiro[4,4]nonane-2,7-dione and 1,6-di[4-hydroxy-3-(2-
hexenyl)phenyl]-3,4,8,9-tetrafluoro-1,6-diazaspiro[4,4]nonane-
2,7-dione.
In the embodiment of the spirodilactam derivatives of formula
I wherein the adjacent Z moieties of each spiro ring form a cyclic,
fused ring substituent, i.e., the adjacent Z groups are Z",
illustrative spirodilactam derivatives include 1,6-di(4-hydroxy- or
4-cyanato-3,5-diallylphenyl)-3,4,8,9-dibenzo-1,6-diazaspiro[4,4]-
nonane-2,7-dione, 1,6-di[4-(4-hydroxy-3-methallylphenyloxy)phenyl]- -
3,4,8,9-di(pyrido)-1,6-diazaspiro[4,4]nonane-2,7-dione and
1,6-di[4-(4-hydroxy-3-allylphenylthio)phenyl]-3,4,8,9-di(cyclo-
pentano)-1,6-diazaspiro[4,4]nonane-2,7-dione. Also suitable are
those substituted spirodilactam derivatives wherein one spiro ring
has a cyclic fused ring substituent and one spiro ring is free of
fused ring substituents, e.g., 1,6-di(4-hydroxy- or 4-cyanato-3-
allylphenyl)-3,4-benzo-8-methyl-1,6-diazaspiro[4,4]nonane-2,7-dione
and 1,6-di[1-(4-hydroxy-3-allylnaphthyl)]-3,4-cyclohexano-1,6-
diazaspiro[4,4]nonane 2,7-dione.
Other representatives illustrative of such unsaturated
spirodilactams of this invention are 1,6-diallyl-1,6-diazaspiro-
[4,4]nonane-2,7-dione, 1,6-di-propargyl-3,8-dimethyl-1,6-di-
azaspiro[4,4]nonane-2,7-dione, 1,6-di(4-styryl)-1,6-diazaspiro-
[4,4]nonane- 2,7-dione, 1,6-di(l-methyl-2-propenyl-3,4,8,9-
2~1~53~
dibenzo-1,6-diazaspiro[4,4]nonane-2,7-dione, 1,6-di[3-(2-propynyl)-
phenyl]- 1,6-diazaspiro[4,4]nonane-2,7-dione and 1,6-di(2-butyl-
2-propenyl)- 3,3-dimethyl-1,6-diazaspiro[4,4]nonane-2,7-dione.
The identity oi other spirodilactam products will be apparent
from consideration of the above formula for the reactants and the
spirodilactam product. Particularly preferred are the 1,6-diallyl
spirodilactam products.
In general, the spirodilactam derivatives of the above formula
wherein Y is -CH~CH2 and n and m are 1 and r is 0 are preferred.
Within the spirodilactam ring portion of the molecule,
spirodilact~m derivatives free from fused ring substituents, i.e.,
Z is C(Z')2, are preferred as are the derivatives in which both
spiro rings incorporate a fused ring substituent. The compound
1,6-di(4-hydroxy-3-allylphenyl)-1,6-diazaspiro[4,4]nonane-2,7-dione
is an especially preferred member of the Eormer class whereas
1,6-di(4-hydroxy-3-allylphenyl)-3,4,~,9-dibenzo-1,6-diazaspiro-
[4,4]nonane-2,7-dione is an especially preferred member of the
latter class.
The ortho-alkenyl hydroxyaryl-substituted spirodilactams are
produced by thermal rearrangement of an alkenyl ether of the
corresponding hydroxyaryl-substituent spirodilactam.
Rearrangement of these alkenyl ethers to the corresponding
ortho-alkenyl hydroxy compound is by the well-known Claisen
Rearrangement. In this process, the alkenyl ether is dissolved in a
suitable reaction diluent and the resulting mixture is heated, in a
liquid phase, until reaction is complete. Reaction diluents that
are satisfactory in the rearrangement process are capable of
dissolving at least a portion of the alkenyl ether reactant and are
inert to the reactant and ortho-alkenyl hydroxy compound product.
Such diluènts include ethers, for example acyclic ethers such as
diethylene glycol diethyl ether and tetraethylene glycol dimethyl
ether as well as cyclic ethers such as tetrahydrofuran and dioxane,
N-alkylamide diluents such as N,N-dimethylacetamide, N,N-dimethyl-
formamide and N-methyl-2-pyrrolidone, and sulphur-containing
diluents such as dimethyl sulfoxide and sulfolane. The temperature
,
20~37
of the rearrangement reaction is typically from 150 C to 300 C,
preferably from 175 C to 250 C, depending in part on the
particular ether to be rearranged, and a suitable reaction pressure
is sufficient to maintain the reaction mixture in a liquid phase.
Such pressures are from 1 atmosphere to 20 atmospheres. Subsequent
to rearrangement the resulting ortho-alkenyl hydroxyaryl-
substituted spirodilactam product is recovered by conventional
methods such as extraction, solvent removal or precipitation.
Thus, the production of the ortho-alkenyl hydroxy compounds is
by way of a sequential two-step process. Initially an alkenyl ether
of the hydroxyaryl-substituted spirodilactam is produced by
conversion of the hydroxy compound to a metal salt, preferably an
alkali metal salt such as the sodium or potassium salt, and
reaction of the salt with an alkenyl halide, e.g., allyl chloride
or bromide. The alkenyl ether, in a second step, is rearranged .
according to the process of the invention to produce the
ortho-alkenyl hydroxy compound.
It should be appreciated, however, that the rearrangement to
produce the products of the invention, like other Claisen
Rearrangements, provides an ortho-alkenyl substituent which is
inverted in the sequence of carbon atoms from the alkenyl moiety of
the ether reactant. What was the "gamma" or third carbon atom of
the alkenyl moiety of the ether becomes the carbon atom attached to
the aromatic ring of the ortho-alkenyl derivative. In the case of
the preferred allyl ethers, rearrangement provides an ortho-allyl
derivative and inversion, although present, produces no observable
difference. However, rearrangement of a crotyl ether produces a
2-(3-butenyl)-substituted product. From a straight-chain alkenyl
ether is produced a branched-chain ortho-alkenyl substituent. This
inversion is conventional for Claisen Rearrangements.
Another preferred group of novel compounds are those
spirodilactams of the above formula in which each of r and n equals
0 and m is l, these are compounds in which an allyl or propargyl
group is directly attached to the nitrogen atoms in the spiro
structure. Such compounds can be prepared by reacting a
2~0~i3~
spirodilactam precursor, e.g. a spirodilactam or a ketodiacid, a
primary amine having terminal unsaturation separated from the
primary amino group by one carbon atom or by an aromatic ring.
While a variety of unsaturated amines having a variety of
structures are suitable in the process, a preferred class of
unsaturated primary amine~s are the hydrocarbyl amines represented
by the formula
y- (c~l2)m Rn N 2 (II)
where Y is CH2~C'- or HC~C- and R is phenylene and n is l.
Illustrative of such primary amino compounds are-allylamine,
propargylamine, p-styrylamine, methallylamine and
m-aminophenylacetylene. This reaction is accomplished by contacting
the unsaturated primary amine and the spirodilactam precursor under
reaction conditions in a liquid phase in the presence of a reaction
diluent. The reactants combine to form the substituted
spirodilactam in a molar ratio of 2:l although in practice the
unsaturated primary amine and the spirodilactam precursor reactants
are provided to the reaction mixture in molar ratios of from 8:l to
l:2. Reactant ratios that are substantially stoichiometric, i.e.,
from 2.5:l to 2:l.5 are preferred. The reaction diluent is an inert
reaction diluent which is liquid under reaction conditions and
which is capable of dissolving at least a portion of each reactant
at reaction temperature. Suitable reaction diluents include ethers,
e.g., acyclic ethers such as diethylene glycol dimethyl ether and
tetraethylene glycol dimethyl ether as well as cyclic ethers such
as tetrahydrofuran and dioxane, chlorinated hydrocarbon diluents
such as methylene chloride, chloroform and chlorobenzene,
sulphur-containing diluents such as dimethyl sulfoxide and
sulfolane and N-alkylamides such as N,N-dimethylformamide,
N,N-dimethylacetamide and N-methyl-2-pyrrolidone. It is often
useful to choose a diluent, or employ a second diluent such as an
alkylated benzene, e.g., toluene or ethylbenzene, with which water
forms an azeotrope. It is theraby possible to remove the water
present or formed in the reaction mixture as an often low-boiling
azeotrope. Removal of water by conventional fractionation or by
0~37
- 7
extraction is also suitable. The reaction temperature to be
employed is typically from 50 C to 250 C but more often from
125 C to 200 C. A suitable reaction pressure is one which will
maintain the reaction mixture in the liquid phase at reaction
temperature. Such pressures are up to 20 atmospheres but preferably
are from 0.8 atmosphere to 10 atmospheres. Subsequent to reaction
the unsaturated spirodilactam product is recovered by conventional
methods such as extraction, solvent removal or precipitation.
The compounds so produced may be further reacted with cyanogen
halide, e.g. cyanogenchloride or cyanogenbromide-to produce the
corresponding cyanato derivatives. This reaction takes place in the
liquid phase in the presence of a tertiary amine employed to react
with the hydrogen halide by-product and facilitate its removal from
the reaction mixture through formation of a quaternary ammonium
salt. Trialkyl amines are satisfactory for this purpose, for
example triethylamine. The cyanogen halide and the spirodilactam
are usually provided in a molar ratio of 2:1 in a diluent such as
an N-alkylamide. Typical reaction temperatures are from 10 C to 15
C at a reaction pressure sufficient to maintain the mixture in the
liquid phase at reaction temperature. Such pressures are generally
from 0.8 atmosphere to 10 atmospheres. Subsequent to reaction the
cyanatoaryl-substituted spirodilactam, e.g., the compound of
formula I, are recovered by conventional methods including the
removal of the quaternary ammonium salt co-produced as by
filtration or decantation and separation of the spirodilactam
derivative as by extraction or precipitation with a non-solvent.
The substituted spirodilactams of this invention are normally
solid at room temperature but are curable at elevated temperatures
to produce cured products which exhibit good properties of tough-
ness. Although the alkenyl derivatives are curable with a number ofconventional polyfunctional curing agents such as isocyanates, a
prefe-rred class of curing agents are the bis(maleimides), for
example, di~4-maleimidophenyl)methane. Curing takes place by
heating at temperatures from 200 C to 300 C and generally employs
5 3 7
- 8
approximately equal proportions by weight of the ortho-alkenyl
derivative and the bis(maleimide). The cured products are tough and
show good solvent resistance. The cured products are processed by
methods conventional for thermoset resins to produce coatings,
adhesives and fibre-reinforced composites wherein the fibres are
glass or carbon. The cured products are also useful as impregnating
and casting resins.
The invention is further illustrated by the following Examples
which should not be construed as limiting the lnvention.
EXAMPLE 1
To a three litre flask was charged a mixture of 202.8 g (0.6
mole) of 1,6-di(4-hydroxyphenyl~-1,6-diazaspiro[4,4]nonane-2,7-
dione, 91.22 g (0.6 mole) of potassium carbonate, 200 ml of toluene
and 1 litre of ~,N-dimethylacetamide. The mixture was heated to
150-160 C and water was removed by azeotropic distillation with
the toluene. When the water removal was complete, the temperature
was lowered to 80-90 C and 200.2 g (1.2 mole) of allyl bromide in
200 ml of N,N-dimethylacetamide was added over the next 80 minutes.
The reaction temperature was then raised to 90 C for 12 hours. The
resulting mixture was cooled, filtered and concentrated and was
then poured slowly into a mixture of hexane and ether. The
precipitated product was recovered by filtration and dried in a
vacuum oven at 80 C. The product had a melting point of 152-155 C
and the nuclear magnetic resonance spectra were consistent with the
structure of 1,6-di(4-allyloxyphenyl)-1,6-diazaspiro[4,4]-
nonane-2,7-dione.
EXAMPLE 2
A 141 g sample of the product of Example 1 was dissolved in
~-methyl-2-pyrrolidone and heated at 200-205 C for 12 hours. The
resulting mixture was cooled; concentrated and then poured into 3
litres of water. The precipitated product was recovered by
filtration and dried in a vacuum oven at 80 C. The yield was
greater than 90%. The melting point of the product was 237-245 C
and the infrared and nuclear magnetic resonance spectra were
consistent with the structure of 1,6-di(4-hydroxy-3-allylphenyl)-
1,~-diazaspiro[4,4]nonane-2,7-dione.
2 ~ 3 ~
g
EXAMPLE 3
When a sample of the product of Example 2 is heated with an
equal proportion by weight of di(4-maleimidophenyl)methane, a
tough, crosslinked product will result.
EXAMPLE 4
-
The compound, 1,6-di(4-hydroxy-3-allylphenyl)-1,6-diazaspiro-
[4,4]nonane-2,7-dione, is produced by converting the sodium salt of
1,6-di(4-hydroxyphenyl)-1,6-diazaspiro[4,4]nonane-2,7-dione to the
corresponding di(allyl) ether through reaction with allyl chloride
by conventional methods. The 1,6-di(4-allyloxyphenyl)-1,6-di-
azaspiro[4,4]nonane-2,7-dione was then subjected to a Claisen
Rearrangement by heating to 200 C. The ortho-allyl hydroxy
compound was then contacted at 0 C in the presence of a slight
stoichiometric excess of cyanogen bromide and triethylamine. When
reaction was complete, triethylammonium bromide was removed by
filtration and 1,6-di(4-cyanato-3-allylphenyl)-1,6-diazaspiro[4,4]-
nonane-2,7-dione was precipitated by mixing with ether-hexane.
EXAMPLE 5
A mixture of equal portions by weight of the product of
Example 4 and di(4-maleimidophenyl)methane was melted at
130-150 C. The mixture is then heated in an oven, in a first stage
at 200 C for 2 hours and in a second stage at 220 C for an
additional 6 hours. The resulting product is a hard, insoluble,
crosslinked resin having a glass transition temperature in excess
of 300 C.
EXAMPLE 6
A mixture of equal parts by weight of the product of Example 4
and 2,2-bis(4-cyanatophenyl)propane was melted at 100-120 C. The
resulting mixture was heated in an oven, initially at 200 C for 2
hours and then at 220 C for an additional 4 hours. The resulting
product was a hard, insoluble, crosslinked product having a glass
transition temperature of 216 C.
~0~37
- 10 -
EXAMPLE 7
A mixture of 150 g (0.86 mole) of 4-oxoheptandioic acid, 100 g
(1.75 mole) of allylamine, 200 ml of N,N-dimethylacetamide and
50 ml of toluene is placed in a 500 ml round bottom flask equipped
with a mechanical stirrer and a condenser. The mixture is warmed,
while stirred, to 140-160 C and maintained at this temperature for
16 hours while the water present or formed is removed by azeotropic
distillation. The resulting mixture was cooled and the
N,N-dimethylacetamide was removed under reduced pressure. The crude
product was then dissolved in chloroform and washed several times
with water. Removal of the chloroform provided 200.8 g thick amber
liquid product. The nuclear magnetic resonance spectra of the
products were consistent with the structure N,N'-diallyl-1,6-
diazaspiro[4,4]nonane-2,7-dione.
EXAMPLE 8
A mixture of 50 parts by weight oi the product of Example 7
and 50 parts by weight of di(4-maleimidophenyl)methane was melted
at a temperature of 100-120 C. The mixture was then heated in an
oven at 200 C for 4 hours and at 220 C for an additional 2 hours.
The resulting crosslinked product had a glass transition
temperature of 237 C.
